These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37966357)

  • 41. First-Line Persistence of Biologics in Psoriasis from a Cohort Based on French Medico-Administrative Data.
    Marcombes C; Penso L; Sbidian E
    J Invest Dermatol; 2023 Sep; 143(9):1819-1822.e3. PubMed ID: 36997111
    [No Abstract]   [Full Text] [Related]  

  • 42. A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic [Formula: see text].
    Le H; Vender RB
    J Cutan Med Surg; 2021; 25(3):298-302. PubMed ID: 33504214
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of the COVID-19 pandemic on biologic treatment in psoriasis patients: A single-center retrospective study in Japan.
    Uchida H; Kamata M; Egawa S; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2022 Jun; 49(6):624-628. PubMed ID: 35319126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study.
    Lodde GC; Krefting F; Placke JM; Schneider L; Fiedler M; Dittmer U; Becker JC; Hölsken S; Schadendorf D; Ugurel S; Sondermann W
    Front Immunol; 2023; 14():1107438. PubMed ID: 37006279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biologics and Psoriasis: The Beat Goes On.
    Kim HJ; Lebwohl MG
    Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Durability and long-term outcomes of biologic therapies in psoriasis.
    Rusiñol L; Carmona-Rocha E; Puig L
    Expert Rev Clin Immunol; 2024; 20(1):71-82. PubMed ID: 37610817
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic.
    Rob F; Hugo J; Tivadar S; Boháč P; Gkalpakiotis S; Vargová N; Arenbergerová M; Hercogová J
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):e682-e684. PubMed ID: 32594549
    [No Abstract]   [Full Text] [Related]  

  • 48. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience.
    Gisondi P; Piaserico S; Naldi L; Dapavo P; Conti A; Malagoli P; Marzano AV; Bardazzi F; Gasperini M; Cazzaniga S; Costanzo A;
    J Allergy Clin Immunol; 2021 Feb; 147(2):558-560.e1. PubMed ID: 33160968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Special aspects of biologics treatment in psoriasis: management in pregnancy, lactation, surgery, renal impairment, hepatitis and tuberculosis.
    Plachouri KM; Georgiou S
    J Dermatolog Treat; 2019 Nov; 30(7):668-673. PubMed ID: 30428753
    [No Abstract]   [Full Text] [Related]  

  • 50. No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients.
    Manzanares N; Vilarrasa E; López A; Alonso ML; Velasco M; Riera J; Del Alcázar E; Carrascosa JM; Azón A; Rivera R; Santos S; Salgado-Boquete L; Roncero M; Dorado M; Yelamos O; Delgado C; Gallardo F; Ferran M
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e26-e28. PubMed ID: 37561934
    [No Abstract]   [Full Text] [Related]  

  • 51. The use of biologics for childhood psoriasis.
    Torrelo A
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1816. PubMed ID: 31617632
    [No Abstract]   [Full Text] [Related]  

  • 52. [Psoriasis in the era of biologics].
    Torres T; Velho GC; Sanches M; Selores M
    Acta Med Port; 2010; 23(3):493-8. PubMed ID: 20654269
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Translating the 2019 AAD-NPF Guidelines of Care for the Management of Psoriasis With Biologics to clinical practice.
    Pithadia DJ; Reynolds KA; Lee EB; Wu JJ
    Cutis; 2019 Aug; 104(2S):12-16. PubMed ID: 31634385
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biologics for psoriasis: a translational research success story.
    Lebwohl M
    J Invest Dermatol; 2015 May; 135(5):1205-1207. PubMed ID: 25882456
    [No Abstract]   [Full Text] [Related]  

  • 55. Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea.
    Shin JO; Shin BS; Bae KN; Shin K; Kim HS; Ko HC; Kim MB; Kim B
    Indian J Dermatol Venereol Leprol; 2023; 89(6):928. PubMed ID: 37317715
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.
    Thatiparthi A; Martin A; Liu J; Egeberg A; Wu JJ
    Am J Clin Dermatol; 2021 Jul; 22(4):425-442. PubMed ID: 33861409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic.
    Kado S; Kamiya K; Kishimoto M; Maekawa T; Kuwahara A; Sugai J; Komine M; Ohtsuki M
    J Dermatol; 2021 Dec; 48(12):1907-1912. PubMed ID: 34549456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination.
    Favaro R; Formai A; Pavia G; Gargiulo L; Avagliano J; Valenti M; Facheris P; Salsano B; Latorre RV; Bellinato F; Gisondi P; Narcisi A; Costanzo A
    Br J Dermatol; 2023 Oct; 189(5):635-637. PubMed ID: 37463513
    [No Abstract]   [Full Text] [Related]  

  • 59. New biologics in psoriasis - progress and problems.
    Boehncke WH
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1577-1578. PubMed ID: 29059511
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.